Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04943289 · ClinicalTrials.gov registry record · Phase 1
Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis
A Phase 1 study, sponsored by Joanne Kurtzberg, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT04943289 is a Phase 1 study that has completed, run by Joanne Kurtzberg, MD. The registered enrollment target is 20 participants.
The verdict
NCT04943289, a Phase 1 study, has completed, sponsored by Joanne Kurtzberg, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is a prospective Phase 1a open-label single- center trial. It will assess the safety of intrathecal administration of DUOC-01 cells to adults with Primary Progressive Multiple Sclerosis (PPMS). DUOC-01 is a population of cells expanded from donated human umbilical cord blood cells and is intended for treatment of neurodegenerative and demyelinating diseases. There will be approximately 20 participants enrolled. Exploratory objectives include changes in MS assessment scores, changes in brain MRI findings, and changes in blood biomarkers.
Interventions
- BIOLOGICAL DUOC-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-01-24 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04943289
The ClinicalTrials.gov registry entry for NCT04943289 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joanne Kurtzberg, MD, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DUOC-01 is the first listed.
NCT04943289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04943289 about?
NCT04943289 is a clinical study titled "Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis". This study is a prospective Phase 1a open-label single- center trial. It will assess the safety of intrathecal administration of DUOC-01 cells to adults with Primary Progressive Multiple Sclerosis (PPMS). DUOC-01 is a population of cells expanded from donated human umbilical cord blood cells and is ...
What is the current status of trial NCT04943289?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-01-24. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT04943289?
The interventions under investigation include: DUOC-01 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04943289?
This trial is sponsored by Joanne Kurtzberg, MD, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.